Sebastian B Lacher, Janina Dörr, Gustavo P de Almeida, Julian Hönninger, Felix Bayerl, Anna Hirschberger, Anna-Marie Pedde, Philippa Meiser, Lukas Ramsauer, Thomas J Rudolph, Nadine Spranger, Matteo Morotti, Alizee J Grimm, Sebastian Jarosch, Arman Oner, Lisa Gregor, Stefanie Lesch, Stefanos Michaelides, Luisa Fertig, Daria Briukhovetska, Lina Majed, Sophia Stock, Dirk H Busch, Veit R Buchholz, Percy A Knolle, Dietmar Zehn, Denarda Dangaj Laniti, Sebastian Kobold, Jan P Böttcher
Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer immunity through expansion and effector cell differentiation1-4 ; however, this response is dysfunctional in tumours. Current cancer immunotherapies2,5-9 can promote anticancer responses through TCF1+ stem-like CD8+ T cells in some but not all patients. This variation points towards currently ill-defined mechanisms that limit TCF1+ CD8+ T cell-mediated anticancer immunity. Here we demonstrate that tumour-derived prostaglandin E2 (PGE2 ) restricts the proliferative expansion and effector differentiation of TCF1+ CD8+ T cells within tumours, which promotes cancer immune escape...
April 24, 2024: Nature